Search results
Results from the WOW.Com Content Network
The most common cancer among women in the United States is breast cancer (123.7 per 100,000), followed by lung cancer (51.5 per 100,000) and colorectal cancer (33.6 per 100,000), but lung cancer surpasses breast cancer as the leading cause of cancer death among women. [13]
In Sub-Saharan Africa, the prevalence rate of detectable cryptococcal antigen in peripheral blood is often 4–12% in persons with CD4 counts lower than 100 cells/mcL. [37] [38] Cryptococcal antigen screen and preemptive treatment with fluconazole is cost-saving to the healthcare system by avoiding cryptococcal meningitis. [39]
CD58, lymphocyte-function antigen 3 (LFA-3), is a glycoprotein that plays a vital role in the body's immune response.The natural ligand to CD58, CD2, is most commonly found on the surfaces of both T cells and Natural Killer cells (T/NK cells). [3]
Cryptococcus neoformans is a fungus that causes cryptococcosis, which can lead to pulmonary infection as well as nervous system infections, like meningitis. [25] [26] Histoplasma capsulatum is a species of fungus known to cause histoplasmosis, which can present with an array of symptoms, but often involves respiratory infection. [27] [28]
Invasive carcinoma NST is one of the most common types of all breast cancers, accounting for 55% of breast cancer incidence. [2] Of the invasive breast cancers, invasive carcinoma NST accounts for up to 75% of cases. [3] [4] It is also the most common form of breast cancer occurring in men, accounting for 85% of cases. [5] [6]
breast cancer [9] CA27.29: breast cancer [10] CA19-9: Mainly pancreatic cancer, but also colorectal cancer and other types of gastrointestinal cancer. [11] CA-125: Mainly ovarian cancer, [12] but may also be elevated in for example endometrial cancer, fallopian tube cancer, lung cancer, breast cancer and gastrointestinal cancer. [13] Calcitonin
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.